SOUZA, Hyngryd Rayssa Araújo e.
Resumen:
Based on the doctrines, guidelines and public policies related to pharmaceutical care, the SUS has been organizing to supply essential medicines to the population. Despite the advances in health policies, there is an increase in the demand for the supply of medicines, supplies and health services through lawsuits. Currently, the demands are mainly related to the supply of drugs for the oncology and for diseases of genetic origin, being actions of high cost and constituting new technologies in health. The objective of this study was to characterize the legal demands for antineoplastic drugs in the State of Rio Grande do Norte, analyzing the scientific evidences of the therapeutic indication of these requests. The search for procedural data occurred through the number of processes and / or names of the authors of the actions, available in the database provided by the Central Unit of Therapeutic Agents of the RN (UNICAT). Subsequently, the information was collected on the website of the Court of Justice of the RN, and lawsuits filed against the State of the RN were analyzed, from January to December 2014. A total of 358 drugs were requested, of which 65.09% were not Part of any component of Pharmaceutical Assistance; Of the 125 drugs present in RENAME, 58.4% were from the Specialized Component. According to the (ATC) classification anatomical, therapeutic, chemical, Antineoplastic Agents and Immunomodulators, with 21.78% were the most requested class, and neoplasms (n = 43) were the most frequent diagnosis. There were 35 lawsuits demanding antineoplastic drugs, totaling 13 different drugs, of which only 2 are part of RENAME (gosserelin acetate and Azacitidine). As for the scientific evidence of the indication of medicines that were not part of RENAME, Trastuzumab with indication for the treatment of breast cancer, Bevacizumab for the treatment of malignant neoplasm of the colon and Sunitinib Malate for renal cell cancer were the most Requested. It was also observed that these drugs and indications present favorable evidence of efficacy, with strength of recommendation IIa and strength of evidence B. The data show that in relation to the judicialization of antineoplastics in the NB, there is great demand for the incorporation of new technologies, which Are not being absorbed by the SUS, even though there is good scientific evidence.
